1 Day
Source:
USA TODAY
_1777370220974_847775619.png&w=64&q=75){kind=small}
Source: USA TODAY
1 DayUSA TODAY
Source: USA TODAY
1 DayReady to play
Ready to play
The FDA said Nov. 9 that manufacturers of a dozen GLP-1 drugs, including Ozempic, Wegovy, Mounjaro and Zepbound, must add warnings about the rare risk of non-arteritic anterior ischemic optic neuropathy, which can cause permanent vision loss. Its review found a rate of 6.4 cases per 100,000 patients taking GLP-1 drugs, compared with 3.8 per 100,000 in comparison groups.
Notice: This Is an AI-Generated Summary
Comments (0)